Topoisomerase I inhibitors have been shown to have clinical activity against human colorectal cancer. Previous studies showed that the cytotoxicity of camptothecin, a topoisomerase I inhibitor, occurs mainly in the S -phase of the cell cycle and is protectable by aphidicolin, an inhibitor of replicative DNA polymerase in some camptothecin-sensitive colorectal cells. Transcription factor E2F-1 regulates the G1/S transition, and recent studies have shown that E2F-1 potentiated the cytotoxicity of some cell-cycle-related drugs. Therefore, the present study was designed to investigate the effect of adenovirus-mediated E2F-1 gene transfer on chemosensitivity of colorectal cancer to camptothecin, in vitro and in vivo. Two human colorectal cancer cells, SW620 (mutant p53) and RKO (wildtype p53), were treated with camptothecin, alone or in combination with adenoviral vectors expressing b-galactosidase (Ad-LacZ), or E2F-1 (Ad-E2F-1). E2F-1 overexpression was confirmed by Western blot analysis. Ad-E2F-1 gene transfer at low doses (less than the LD 20 dose) markedly increased the sensitivity of human colorectal cancer cells to camptothecin in vitro, which is because of induction of apoptosis. Aphidicolin did not have any protective effect on the Ad-E2F-1/camptothecin-mediated cytotoxicity. The level of topoisomerase I expression was not affected by combination treatment as well, suggesting that DNA replication and topoisomerase I activity may not account for the molecular mechanism of cell killing in response to Ad-E2F-1/camptothecin treatment. Fas and Fas ligand expression were not altered by treatment with camptothecin and/or Ad-E2F-1. Moreover, combination of camptothecin and Ad-E2F-1 has an additive antitumor effect in an in vivo nude mouse xenograft model. When combined with camptothecin, E2F-1 adenovirus therapy resulted in a 95.7% decrease in tumor size compared to control groups (Po.05). These results suggest a chemosensitization strategy that may have clinical utility in human colorectal cancer.
H uman colorectal cancer is the second most prevalent cancer in Western countries, and is the third leading cause of cancer death. For patients with advanced disease (stage IV), chemotherapy with 5-fluorouracil (5-FU) and leucovorin are commonly administered. The most active cytotoxic drug against this malignancy, the antimetabolite 5-FU, was developed more than 40 years ago, and as a single agent produces responses in only 10-15%. A combination of 5-FU/leucovorin enhances response rates about two-fold, without, however, significantly improving survival rates. 1, 2 More recently, the topoisomerase I agent irinotecan given in combination with 5-FU/leucovorin has been found to improve the response rate of patients with metastatic colorectal cancer. 2, 3 However, this combination therapy is significantly more toxic than 5-FU/ leucovorin, with only a modest improvement in survival.
Furthermore, cancer progression is often associated with the development of resistance to chemotherapeutic agents. Although the cellular resistance mechanisms involved in cancer chemoresistance are not yet clearly defined, data indicate that defects in apoptosis pathways may be a contributing factor. [4] [5] [6] [7] Therefore, gene therapy using proapoptotic genes that can either trigger apoptosis in chemotherapy-resistant cells, or reconstitute apoptotic pathways to enhance the effect of chemotherapy, is an attractive strategy.
Camptothecin is similar to irinotecan, and has activity against colon cancer. 8, 9 Camptothecin is a specific inhibitor of eukaryotic DNA topoisomerase I, a ubiquitous enzyme with key roles in DNA replication, transcription, and DNA repair. [10] [11] [12] [13] Topoisomerase I poisons are believed to exert their cytotoxicity by creating DNA breaks after trapping of topoisomerase I to DNA in a drug-enzyme-DNA cleavable complex. [11] [12] [13] DNA breaks occur by collisions between these cleavable complexes and replication forks. This DNA damaging mechanism, at least in some cell types, accounts for the maximum toxicity of camptothecin during the S phase of the cell cycle. [14] [15] [16] Therefore, topoisomerase I poisons are considered to be S-phase-specific agents. Sensitivity to topoisomerase I inhibitors is also related to intracellular topoisomerase I levels. Resistance to camptothecin in cell lines selected by drug exposure is generally a result of decreased topoisomerase I expression and/or mutations of the topoisomerase I gene. [17] [18] [19] The E2F-1 family of transcription factors modulates cell growth and cell cycle progression. The best-characterized member of this family, E2F-1, activates transcription of genes involved in the G1-to S-phase transition. 20, 21 Overexpression of E2F-1 has been shown to induce apoptosis in many tumor cells. [22] [23] [24] [25] [26] Recent studies also showed that E2F-1 might play a role in mediating cytotoxicity to some DNA-damaging agents, such as topoisomerase II inhibitors and ionized radiation. [27] [28] [29] [30] [31] [32] Our previous studies have shown that adenovirusmediated E2F-1 gene transfer efficiently induces apoptosis in human colorectal cancer. 33 In the present studies, the in vitro and in vivo cooperative effects of adenovirusmediated E2F-1 and a topoisomerase I inhibitor (camptothecin) were evaluated. Our observations clearly show that adenovirus-mediated E2F-1 gene transfer can markedly sensitize human colorectal cancer cells to camptothecin, leading to a cooperative effect on apoptotic cell death in vitro. However, neither changes in the Sphase fraction nor topoisomerase I levels account for this cooperative effect. Moreover, camptothecin cooperated with Ad-E2F-1 to enhance antitumor effect in an in vivo nude mouse xenograft model. These data support a new chemosensitization strategy for human colorectal gene therapy.
Materials and methods

Cell lines and culture conditions
Human colon cancer cell lines RKO (wild-type p53) and SW620 (mutant p53) were purchased from ATCC (Rockville, MD). RKO cells were cultured in RPMI 1640 medium and SW620 cells were cultured in McCoy's 5A medium. The media were supplemented with 10% heatinactivated fetal bovine serum (FBS) and penicillin/ streptomycin (100 U/ml). All cell culture reagents were obtained from Gibco/BRL (Bethesda, MD) and all chemotherapeutic agents from Sigma (St Louis, MO). Cells were cultured in a 5% CO 2 incubator at 371C, and the medium was changed every 3 days.
Chemotherapeutic agents
Camptothecin was purchased from Sigma (St Louis, MO), dissolved in DMSO at the concentration suggested by the manufacturer, and stored at À201C. The drug was diluted in culture medium before addition to the cell cultures.
Adenoviral vectors
Two replication-defective recombinant adenoviral vectors were used. Ad5CMV-E2F-1 vector has been deleted in the E1 subunit and contains the transgene E2F-1 under the control of the CMV promoter. Ad5CMV-LacZ (generously provided by Dr Brent French) was used as a control vector that expresses nuclear-localized b-galactosidase under the control of the same promoter. All vectors were propagated in the 293 cell line and titers were determined using standard plaque assays.
b-Galactosidase assay
The cell lines infected with Ad-LacZ were assayed for bgalactosidase expression by the X-gal staining method. RKO and SW620 cells were infected with Ad-LacZ, Ad-E2F-1 or mock infection, 48 hours after infection, the cells were washed with phosphate-buffered saline (PBS) and fixed in 2% (vol/vol) formaldehyde and 0.2% (vol/ vol) glutaraldehyde in PBS, pH 7.4 for 5 minutes at 41C. The cells were then washed and stained with X-gal solution (1 mg/ml 5-bromo-4-chloro-3-indolyl-b-galactopyranoside, 5 mM K 4 Fe(CN) 6 , 5 mM K 3 Fe(CN) 6 , 2 mM MgCl 2 in PBS, pH 6.5) for 12-18 hours at 371C. Blue staining of cell nuclei identified transduced cells. Mockinfected cells and cells transduced with Ad-E2F-1 virus vector served as controls.
Adenovirus infections and combined treatments
For infection, cells (3 Â 10 6 for RKO and 5 Â 10 6 for SW620) were plated in 10 cm tissue culture plates. The following day, the media were removed, and the adenoviral vectors (Ad-E2F-1 or Ad-LacZ) were added in 1 ml a-MEM at a multiplicity of infection (MOI) of 5 for SW620 and an MOI of 10 for RKO. Mock infection was performed by treatment of cells with vehicle (medium) only. At 1 hour after incubation at 371C, the medium was removed, and 10 ml fresh RPMI 1640 or McCoy's 5A with 5% FBS was added. For the combined treatments, cells were infected with viruses as described above, and then 1 hour later the medium was replaced with 10 ml fresh RPMI 1640 or McCoy's 5A with 5% FBS containing campthothecin at selected concentration. Cells were then cultured at 371C and harvested at a 3-day time point for analysis.
Western blot analysis
Cells were harvested at 3 days after treatments and cell lysates were prepared as described previously. 24 Equal amounts of cellular protein (50 mg) were electrophoresed in sodium dodecylsulfate (SDS)-polyacrylamide gels and transferred to a Hybond-PVDP membrane (Amersham, Arlington Heights, IL). The membrane was first incubated with the following primary antibodies: mouseanti-human-E2F-1 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and mouse-anti-humanp53 monoclonal antibody (Calbiochem, San Diego, CA), mouse-anti-human-Fas ligand (FasL) and Fas monoclonal antibody (Calbiochem, San Diego, CA), and then with anti-mouse I, peroxidase-linked, species-specific whole antibody (Amersham, Arlington Heights, IL). Enhanced chemiluminescence (ECL) reagents were used to detect the signals according to the manufacturer's instructions (Amersham).
Cell viability assays
Cell viability was monitored by two methods. First, cell viability was measured by trypan blue exclusion assay. RKO (3 Â 10 5 cells/well) or SW620 (5 Â 10 5 cells/well) cells were plated into six-well plates in duplicate wells; cells were treated with camptothecin or adenovirus vector alone or in combinations. Cell viability and total viable cell number was determined at days 2 and 3. Cells were stained with trypan blue (0.2% final concentration) for 5 minutes and counted using a hemacytometer. Second, cell viability can also be reflected by the integrity of the mitochondria by measuring the conversion of the tetrazolium salt WST-1 to formazan. Cells were treated with camptothecin at indicated concentrations, and 2 days later cells were trysinized, washed with warmed PBS, and plated into 96-well plates with drug-free medium at 3000 cells/well in 100 ml. After 4 hours incubation at 371C, 10 ml WST-1 (Boehringer Mannheim, Indianapolis, IN) was added to each well and incubated at 371C for 3hours. Cell viability was assessed by measuring the conversion of the tetrazolium salt WST-1 to formazan through the measurement of absorbance at 415 nm. Results are expressed as the percentage of the absorbance of control (untreated) cells.
Clonogenic assays
Cells were plated in log phase into six-well plates with 5 ml medium for 24 hours, rinsed with fresh medium, and then treated with various doses of camptothecin for 48 hours. Cells were then washed twice with prewarmed PBS, trypsinized, diluted, and 200 or 400 cells per treatment were seeded into six-well plates in triplicate with camptothecin-free medium. Colonies were allowed to grow for 10-14 days. Cells were then washed with PBS, fixed with methanol (95%), and stained with 0.005% methylene blue. The survival fraction for each cell line was expressed as the ratio of plating efficiency of treated cells to that of untreated control cells.
MTT assay
MTT assay is also used for the measurement of cytotoxicity of drug alone or in combination treatments. Briefly, RKO cells were plated into six-well plates in duplicate wells (3 Â 10 5 cells/well) and infected with Ad-E2F-1 at an MOI of 10 or treated with mock infection. At 1 hour later, cells were exposed to 40 nM camptothecin, along with or without aphidicolin at indicated concentrations in 3 ml fresh RPMI 1640 medium with 5% FBS. After 2 days incubation at 371C, 300 ml MTT (5 mg/ml, Sigma, St Louis, MO) was added to each well and incubated at 371C for 4 hours. After incubation, 1.5 ml lysing buffer (10% SDS in 0.01 N HCl) was added and samples were incubated at 371C overnight for complete cell lysis. On the following day, cytotoxicity was assessed by measuring the conversion of the tetrazolium salt MTT to formazan through the measurement of absorbance at 570 nm. Results are expressed as the percentage of the absorbance of control (untreated) cells.
Cell cycle analysis and apoptosis assay
Both adherent and nonadherent cells were harvested, washed once with PBS, and fixed in 70% (vol/vol) ethanol at À201C for up to 1 week. Cells were pelleted, washed once with PBS, and resupended in propidium iodide (PI) solution (50 mg/ml PI, 0.5 mg/ml RNase in PBS, pH 7.4) for 30 minutes in the dark. FACS analysis was performed at 3 days following treatments. Flow cytometric analysis was performed on a FACScan Flow Cytometer (Beckton Dickinson, San Jose, CA). The data from 10,000 cells were collected and analyzed using CellFIT Cell-Cycle Analysis Software (Version 2.01.2). The DNA content of the subdiploid peak, which indicated apoptotic cells, was determined by FACS analysis.
In vivo combined treatment of transplanted human colorectal cells
To evaluate the ability of AdCMV-E2F-1 plus camptothecin to suppress tumor growth in vivo, we injected 1 Â 10 7 RKO cells into the flanks of athymic BALB/c nu/ nu male mice (6-8 weeks, Charles River Laboratories, Wilmington, MA) to form tumors. Anesthesia was induced by intraperitoneal (i.p.) injection of ketamine (37.5 mg/g) and xylazine (5 mg/g). The cells were injected subcutaneously into the bilateral flanks of the mice. After 12 days, palpable tumors (about 250 mm 3 ) were randomized to be directly injected with AdCMV-E2F-1 (1 Â 10 9 PFU), AdCMV-LacZ (1 Â 10 9 PFU) or control (0.9% saline). Subcutaneous injections were performed every 5 days, with a total of four treatments. Each injection of purified virus was diluted in a total volume of 200 mL 0.9% saline and administered in a single pass of a 27-gauge hypodermic needle using gentle, constant infusion pressure. Beginning on day 13, mice were treated with camptothecin (0.4 mg/g body weight) or 0.9% normal saline via the i.p. route once every 5 days, for a total of four treatments. Tumors were measured every 5 days, and tumor size was calculated using the following formula: length (mm) Â width (mm 2 )/2. Animal survival was closely monitored and no signs of systemic toxicity were observed in animals receiving the recombinant adenoviruses followed by the treatment with camptothecin. Animal experiments were performed in accordance with institutional guidelines and approved by the University Committee on the Use and Care on Animals.
Statistical analysis
Statistical analysis was performed by Student's t-test. Po.05 was considered to be statistically significant.
Results
Camptothecin inhibits colorectal cancer cell growth by G2 arrest
To detect the in vitro cytotoxicity effect of the topoisomerase I inhibitor on human colon cancer cells, we used different doses of camptothecin to treat RKO and E2F-1 overexpression sensitizes colorectal cancer cells YB Dong et al SW620 cells. Both dead and alive cells are counted using a hemocytometer to establish the cell growth inhibition curve. Cell viability after 2 days treatment was assessed by the trypan blue exclusion method (Fig 1a) , and also reflected by the integrity of the mitochondria by measuring the conversion of the tetrazolium salt WST-1 to formazan (Fig 1b) . In RKO cells, the IC 50 (the concentration at which cell growth will be inhibited 50%) of camptothecin was 40 nM. Less than 10% of cells were dead at this drug concentration. In SW620 cells, the IC 50 of camptothecin was approximately 10 nM. Less than 20% of cells lost their viability at this concentration. Increased doses of camptothecin potentiated cell growth inhibition without obvious loss of cell viability in RKO cells. Previous studies showed that camptothecin could lead to both G1 and G2 arrest. 34, 35 To determine if cell growth inhibition in vitro is because of cell cycle arrest by camptothecin, cell cycle analysis was performed. As shown in Figure 1c , camptothecin caused G2 arrest in both colon cancer cell lines. The increase of G2 population was concomitant with the decrease of G1 population. Increasing doses of camptothecin potentiated G2 cell cycle arrest in both cell lines. These data suggest that the topoisomerase I poison can inhibit cell growth by arresting the cell cycle in G2 phase. Although most camptothecin-treated cells did not die, as shown by our trypan blue exclusion and WST-1 assay, it is possible that cells blocked in G2/M phase by camptothecin may not be able to escape from G2/M arrest later. To test if cells were able to recover from G2 arrest after camptothecin treatment, we carried out a clonogenic survival assay. However, the survival fraction for RKO cells after camptothecin treatment is about 15%, and most of the camptothecin-treated cells remained attached to the plate as viable single cells and did not grow to form colonies because of cell cycle arrest. This observation was consistent with other studies, which showed that, in some cell lines, chemotherapeutic agent or radiation treatment may induce a permanent cell cycle arrest. Although lacking colony-forming ability in vitro, cells in cell cycle arrest remain viable single cells in clonogenic assays.
36-38
Adenovirus-mediated E2F-1 gene transfer sensitizes colon cancer cells to camptothecin by efficiently killing cells Our previous study showed that overexpression of E2F-1 by adenovirus-mediated gene transfer can increase the sensitivity of tumor cells to topoisomerase II poisons. 27, 28 In the present studies, we examined whether exogenous E2F-1 overexpression could increase the sensitivity of human colon cancer cells to topoisomerase I inhibitorcamptothecin. We have shown previously that Ad-E2F-1 alone can efficiently kill colon cancer cells in a dose-dependent manner. 33 In order to investigate the possibility of the additive or cooperative effect of Ad-E2F-1 and camptothecin, a low concentration of Ad-E2F-1, by which the E2F-1 protein was overexpressed without obvious cytotoxicity, was used in the combination treatments. Based on the dose-response curves, we found that an MOI of 5 for SW620 and an MOI of 10 for RKO resulted in significant overexpression of E2F-1 (Fig 2a) , but less than 15% loss of cell viability occurred at this concentration compared to controls (data not shown). The transduction efficiency of each cell line at selected virus concentration was monitored by b-galactosidase assay, as shown in Figure 2b . Over 80% cells can express transduced gene in both cell lines at selected concentration. Accordingly, these adenovirus concentrations were used in the following combination treatments. 
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Cell morphology showed that less than 20% cells treated by a combination of Ad-E2F-1 and camptothecin were still adherent to the culture dishes, and most exhibited cell shrinkage; however, more than 90% cells treated by Ad-E2F-1 or camptothecin alone were adherent to the dish by day 3 (data not shown). Cell viability was then assessed by the trypan blue exclusive method. As shown in Figure 2b , c, the combined treatment of adenovirus-E2F-1 and camptothecin resulted in a much greater loss of cell viability and cell growth inhibition compared to camptothecin alone in both cell lines, and the cell killing effect was potentiated by increasing doses of camptothecin. The control virus, Ad-LacZ, had minimal effect on the sensitivity of colon cancer cells to camptothecin compared to camptothecin treatment alone. These data indicated that Ad-E2F-1 sensitized colon cancer cells to camptothecin by efficiently killing cells.
The loss of cell viability by a combination of Ad-E2F-1 and camptothecin is because of apoptosis Previous studies from our laboratory indicated that infection with Ad-E2F-1 at high concentration (MOI of 100) induced apoptosis in human colon cancer cell lines. 33 To investigate the mechanism of increased chemosensitivity to camptothecin by adenovirus-mediated E2F-1 gene transfer, cell cycle analysis was performed. As shown in Figure 3a , treatment with Ad-E2F-1 alone or camptothecin alone produced less than 10% sub-G1 population in both cell lines. However, 63.4 and 42.0% sub-G1 population (indicative of apoptosis) was evident in RKO and SW620 cells, respectively, after the combination treatment with Ad-E2F-1 and camptothecin. These results indicate that Ad-E2F-1 combined with camptothecin acts cooperatively to induce apoptosis. Cell morphology demonstrated typical changes characteristic of apoptotic cell death, including cell shrinkage, cytoplasm blebbing, chromatin condensation, nuclear fragmentation, and formation of apoptotic bodies (data not shown). These changes were more obvious in the combination treatments than in either Ad-E2F-1 or camptothecin treatment alone, and were not seen at all in mock-infected or Ad5CMV-LacZ-infected cells. Furthermore, in both cell lines, an apoptosis-specific PARP cleavage fragment (85-90 kDa) was present in the combined treatment, but not in the controls, or adenovirus-E2F-1 or drugs alone, thus confirming that cell death was because of apoptosis (Fig 3b) .
Aphidicolin, an inhibitor of replicative DNA polymerase, does not have any protective effect on the Ad-E2F-1/camptothecin-mediated cytotoxicity Previous studies showed that camptothecin cytotoxicity relied on DNA replication; aphidicolin, an inhibitor of replicative DNA polymerases, abolished camptothecininduced cytotoxicity.
11,14-16,34 E2F-1 plays an important role in G1/S-phase transition by transactivating genes important for DNA synthesis, including DNA polymerases. 21 Therefore, we tested whether sensitization of 
colorectal cancer cells to camptothecin by E2F-1 is because of enhancement of DNA synthesis by E2F-1. RKO cells were treated with Ad-E2F-1 at an MOI of 10 or were treated by mock infection. After 1 hour, cells were exposed to 40 nM camptothecin, with or without aphidicolin at indicated concentrations. After 2 days, cells were harvested and cytotoxicity was assessed by MTT assay. As shown in Figure 4 , in the presence of aphidicolin, no significant protection was evident in RKO cells treated by Ad-E2F-1 plus camptothecin. These data suggest that factors other than DNA replication might contribute to sensitization of colorectal cancer cells to camptothecin by Ad-E2F-1.
Adenovirus-mediated E2F-1 gene transfer did not affect the level of topoisomerase I expression
Previous studies have shown that the level of topoisomerase I expression correlated with sensitivity to camptothecin in some tumor cells. Resistance to camptothecin in 
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cells is generally correlated with decreased expression of topoisomerase I and/or mutations of topoisomerase I gene. [17] [18] [19] To investigate if E2F-1 sensitize colorectal cancer cells to camptothecin by upregulation of topoisomerase I expression, we performed Western blot analysis. The level of topoisomerase I expression was constant in RKO cell lines (Fig 5) and SW620 cell lines (data not shown) regardless of treatment with camptothecin or E2F-1, suggesting that the level of expression of topoisomerase I is not related to the sensitization of cells to camptothecin by E2F-1.
The combination treatment of adenovirus-mediated E2F-1 and topoisomerase I inhibitor induces apoptosis independent of p53 and may not be related with the Fas/FasL pathway It had been thought previously that p53 was essential for E2F-1-mediated apoptosis. [39] [40] [41] Recent studies, however, showed that p53 is not always required. [22] [23] [24] [25] 42 In the present study, the SW620 cell line contains a mutant p53 gene, and the RKO cell line contains a wild-type p53 gene and expresses functional p53 protein. 43 However, both cell lines are more sensitive to camptothecin in the presence of E2F-1 overexpression. Although camptothecin alone at selected doses can block both colon cancer cell lines in the G2 phase, no increase of p53 protein level was detected after either camptothecin and virus vector treatment alone or in combination in RKO cells, and p53 levels were unchanged in SW620 cells (mutant p53), as shown in Figure 6 . These data are consistent with previous reports that p53 may not be required for camptothecin-induced G2 arrest and E2F-1-mediated apoptosis. [24] [25] [26] 33, 35 A more recent study suggested that camptothecin alone at a high dose of 1 mM can induce apoptosis, which involves upregulation of the Fas and FasL. 44 To see whether the Fas/FasL pathway is also involved in the combination treatment-mediated apoptosis, we performed Western blot analysis for Fas and FasL expression. As shown in Figure 6 , the level of Fas and FasL remains unchanged in the combination treatment group, suggesting they may not be involved in this process.
Combination of adenovirus E2F-1 and camptothecin has an additive antitumor effect in vivo
To evaluate the antitumor effect of Ad-E2F-1 plus systemic camptothecin in vivo, a colon cancer model was formed by injecting 1 Â 10 7 RKO cells into athymic BALB/c nu/nu male mice (6-8 weeks, Charles River Laboratories, Wilmington, MA). Subcutaneous tumors in bilateral flanks of mice were randomized and treated with local injection of 0.9% saline (control), LacZ adenovirus (vehicles) or E2F-1 adenovirus, followed by an i.p. injection of camptothecin or 0.9% saline as described in the Materials and methods section. Previous studies showed that camptothecin alone at 4 mg/kg can completely induce tumor remission in colon cancer nude mouse models. 45 In this study, we want to investigate the possibility of the cooperative antitumor effect of camptothecin and Ad-E2F-1 on colon cancer, so a lower dose of camptothecin was needed. The doses we used in this study were based on our preliminary experiments. At these doses, Ad-E2F-1 and camptothecin treatment alone result in approximately 50% tumor growth inhibition, and no obvious weight loss of mice treated with either camptothecin, Ad-E2F-1 alone, or Ad-E2F-1 in combination with camptothecin was observed at selected doses. As shown in Figure 7a , treatment with Ad-E2F-1 or camptothecin alone reduced mouse tumor size by 55 and 65%, respectively, after four cycles of treatments compared to mock treatment controls. Combination of camptothecin with Ad-LacZ reduced tumor burden by 61%, which was not significantly different compared to camptothecin treatment alone (P4.05). However, when combined with Figure 5 Effect of CPT, Ad-E2F-1 treatment alone or in combination on topoisomerase I expression. RKO cells were treated as indicated; cell lysates were prepared as described in Materials and methods. Western blot analysis was used to detect the expression of topoisomerase I level. a-Actin was used to show equal protein loading in each lane of the gel. 
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Ad-E2F-1, camptothecin resulted in a 96% decrease in tumor size. The differences in tumor size between a combination of Ad-E2F-1/camptothecin and camptothecin or Ad-E2F-1 treatment alone were statistically significant (Po.05) (Fig 7a) . Tumors were excised on day 37 (Fig 7b) . Treatment with Ad-LacZ plus camptothecin did not significantly reduce tumor mass compared to camptothecin alone. However, with Ad-E2F-1/ camptothecin combined treatment, there was a significantly reduced tumor mass compared to all other groups (Po.005; Fig 7c) .
Discussion
Transduction of genes that sensitize tumor cells to chemotherapeutic agents represents a promising strategy for cancer gene therapy. In the present studies, we demonstrated that transduction of the E2F-1 gene significantly enhances the sensitivity of human colorectal cancer cells to the topoisomerase I inhibitor-camptothecin, and this combination treatment results in significant cooperative antitumor effect in vitro and in vivo. This represents a novel chemosensitization strategy that is potentially useful in human cancer. Overexpression of E2F-1 has been shown to induce apoptosis in several cell types, both normal and malignant. [22] [23] [24] [25] [26] 40 The mechanisms by which E2F-1 induces apoptosis are not fully understood, but it has been suggested that apoptosis results from incompatible signals for proliferation and cell cycle arrest. Our previous studies have shown that adenovirus-mediated E2F-1 gene transfer resulted in rapid and efficient apoptosis of human colorectal cancer. 33 We also found that E2F-1-mediated apoptosis was p53-independent. [24] [25] [26] 33 Many chemotherapeutic agents kill cancer cells by activating apoptosis. [4] [5] [6] [7] Camptothecin, a topoisomerase I inhibitor similar to irinotecan, is commonly used in experimental model systems to induce and study the apoptosis pathways. It traps topoisomerase I catalytic intermediate complexes with DNA, which are commonly referred to as the topoisomerase I cleavage complexes. Hence, camptothecin converts topoisomerase I from an essential enzyme into a DNA damaging protein when replication complexes collide with the drug-stabilized cleavage complexes. [10] [11] [12] [13] [14] [15] [16] The mechanism of cytoxicity to camptothecin is not yet clear. Studies showed that two factors were related to camptothecin sensitivity. First, collisions between advancing replication forks and trapped topoisomerase Icleavable complexes are considered a critical step for cytotoxicity. This DNA-damaging mechanism, at least in some cell types, accounts for the maximum toxicity of camptothecin during the S phase. [14] [15] [16] This toxicity mechanism has been shown to be protectable by aphidicolin, an inhibitor of replicative DNA polymerases. 15, 34 Second, studies showed that the camptothecin sensitivity is also correlated with topoisomerse I levels, altered topoisomerase I gene, or reduced topoisomerase I Figure 7 In vivo antitumor effect of the combination treatment of adenovirus-E2F-1 (Ad5CMV-E2F-1) and camptothecin. Following subcutaneous administration of 1 Â 10 7 RKO cells, palpable tumors were randomized to receive a local injection of controls (saline), Ad5CMV-LacZ, and Ad5CMV-E2F-1 followed by i.p. injection of camptothecin. Athymic nude mice (BALB/c) were given six treatments over a period of 1 month. The total virus dose was 6 Â 2 Â 1 Â 10 9 PFU viral particles. The mice were monitored; the tumors were measured (a) on day 37, the tumors were excised (b) and weighed (c). The results are expressed as the mean from each treatment group+standard deviation (a, c). The differences in size or weight in RKO tumors treated by the combined treatment of Ad5CMV-E2F-1 and camptothecin compared to the controls were highly statistically significant by the end of the experiments (day 37, po.005).
E2F-1 overexpression sensitizes colorectal cancer cells YB Dong et al activity. [17] [18] [19] However, neither the S-phase fraction nor topoisomerse I levels are sufficient to predict camptothecin cytotoxicity. 16 Our current results demonstrate marked sensitization of human colorectal cancer to camptothecin by adenovirus-mediated E2F-1 gene transfer both in vitro and in vivo. This combination treatment induced apoptotic cell death to a significantly greater extent than either treatment alone. Since E2F-1 plays an important role in G1/S transition, we thought it is possible that sensitization to camptothecin by E2F-1 is related to E2F-1-induced S-phase entry. However, our results indicating that aphidicolon did not have a protective effect on Ad-E2F-1/camptothecin toxicity argues against this. Ad-E2F-1 and Ad-E2F-1/camptothecin combination treatment did not alter the levels of topoisomerase I either. In summary, our data suggest that neither of the known mechanisms of sensitization to camptothecin (alterations in DNA replication or topoisomerase I activity) accounts for the molecular mechanism of cell killing in response to Ad-E2F-1/camptothecin treatment.
The enhanced sensitivity of human colorectal cancers to the topoisomerase I inhibitor by adenovirus-mediated E2F-1 gene transfer may be the result of molecular events during the late S phase and the G2 phase. It has been demonstrated that mutations in E2F-1 that block cyclin A binding trigger an S-phase cell cycle checkpoint, which leads to cell cycle G2 arrest, apoptosis, and sensitivity to DNA-damaging agents. 46 Some studies have revealed that camptothecin inhibits the resealing of single-strand DNA breaks mediated by topoisomerase I, which was identified as the specific intracellular enzyme target for the drug. Camptothecin stabilizes cleavage complexes, resulting in single-strand DNA breaks that cannot be religated in the presence of the drug. [10] [11] [12] [13] [14] [15] 47 It has been reported that camptothecin cytotoxicity is related to two types of defects: during S phase, accumulation of damaged replicons and failure to complete elongation of replicating DNA; and during G2 phase, deficiency to downregulate cyclin B/cdc2 kinase and reduced G2 arrest. 34 So it is possible that the topoisomerase I inhibition coupled with DNA damage and unregulated E2F-1 activity may also trigger an S-phase cell cycle checkpoint and arrest cell cycle at G2 phase, followed by apoptosis.
Although p53 classically has been thought to be involved in E2F-1-induced apoptosis, it is now clear that p53 is not always required. It has been demonstrated that E2F-1 induced p53-independent apoptosis in SAOS-2 cells (p53 and Rb null) and p53 null mice. 42 Furthermore, adenovirus-mediated E2F-1 gene transfer has recently been shown to induce apoptosis in human melanoma, glioma, breast cancer, ovarian cancer, esophageal cancer, and head and neck cancer cells in a p53-independent manner. [22] [23] [24] [25] [26] In the present study, two colon cancer cell lines we used have different p53 status: the RKO cell line contains wild-type p53 and expresses functional p53 protein, while SW620 contains mutant p53. However, both cell lines were sensitive to camptothecin/Ad-E2F-1 combination treatment, suggesting that p53 function is not required for this process. Although camptothecin alone caused G2 arrest in RKO cells at doses of 20 and 40 nM, no accumulation of wild-type p53 protein was detected in the RKO cell line regardless of treatments. Camptothecin treatment alone also blocked SW620 cells (mutant p53) in the G2 phase. These results are consistent with the study of Jaks et al, 35 which showed that the accumulation of the p53 protein by camptothecin is dosedependent in many cell lines. Cellular accumulation of p53 protein is detectable only at higher concentrations of camptothecin, and low levels of camptothecin are incompetent to induce the increase of p53 protein.
Although campthothecin can block cells in both G1 and G2 phases, camptothecin-induced G1 arrest relies on the accumulation of functional p53, while camptothecininduced G2 arrest is p53 independent. Camptothecin can cause G2 arrest in p53 null cells regardless of camptothecin concentrations used. At low camptothecin concentrations, p53-positive cells also arrest in G2, suggesting that p53 is not involved in camptothecininduced G2 arrest. 35 We also evaluated the in vivo antitumor effects of combination therapy with Ad-E2F-1 and camptothecin. It has been well documented that adenovirus-mediated E2F-1 has antitumor efficacy in a variety of tumors attributable to both the E2F-1 tumor suppressor gene and the adenovirus delivery vector. From this point of view, the adenovirus-mediated E2F-1 could be regarded as a drug. Our in vivo experiments were designed to mimic the clinical situation in which efficacy of the adenovirus drug (with or without chemotherapy) will be compared to clinical outcome with traditional chemotherapy. In the animal model of human colorectal cancer, E2F-1 adenovirus alone or a single topoisomerase I inhibitor alone had some level of antitumor effect. There was, however, a significantly enhanced response when these modalities were combined. These data offer the possibility of enhanced antitumor activity with lower doses of both topoisomerase I inhibitors and E2F-1 adenoviruses. This has the potential to decrease dose-dependent chemotherapy side effects, increase patient quality of life and, perhaps, increase the efficacy of cancer chemotherapy. This strategy also requires lower levels of expression of the adenoviral-delivered transgene to the tumors, which may make adequate gene delivery to the site of the tumors more feasible.
In conclusion, the combination of adenoviral vectormediated E2F-1 gene transfer and the topoisomerase I agent camptothecin provides a novel chemogene therapy strategy that holds promise for the treatment of human tumors. 
